However, blocking TGF-β with the TGF-β receptor inhibitor SM16 leads to aggregation of neutrophils with an anti-tumor phenotype, so in this case, if neutrophils are removed, tumor growth is promoted [64]. The gene discussed is TGFB1; the disease is neoplasm.